BRIEF published on 01/12/2026 at 07:35, 9 months 17 days ago Renouvellement de l'AMM de Sibnayal® dans l'Union Européenne Advicenne Maladies Rénales EMA AMM Sibnayal®
PRESS RELEASE published on 01/12/2026 at 07:30, 9 months 17 days ago Informations privilégiées / Autres communiqués Advicenne annonce le succès du renouvellement de l’AMM de Sibnayal® dans l’Union Européenne. L'EMA a validé l'autorisation de mise sur le marché, renforçant le développement commercial de Sibnayal® Renouvellement Union Européenne Advicenne AMM Sibnayal
BRIEF published on 11/04/2025 at 11:35, 11 months 24 days ago Advicenne submits Sibnayal® to the US FDA FDA Advicenna Sibnayal® Renal Tubular Acidosis Registration Filing
BRIEF published on 11/04/2025 at 11:35, 11 months 24 days ago Advicenne soumet Sibnayal® à la FDA américaine FDA Advicenne Sibnayal® Acidose Tubulaire Rénale Dépôt D'enregistrement
PRESS RELEASE published on 11/04/2025 at 11:30, 11 months 24 days ago Inside Information / Other news releases Advicenne submits registration application for Sibnayal® in dRTA treatment to US FDA, designated orphan drug. Evaluation process expected to take 12 months Advicenne Sibnayal® US FDA DRTA Treatment Registration Application
PRESS RELEASE published on 11/04/2025 at 11:30, 11 months 24 days ago Informations privilégiées / Autres communiqués Advicenne dépose le dossier d'enregistrement de Sibnayal® auprès de la FDA américaine pour le traitement de l'ATRd. Webconférence le 5 novembre 2025. Informations sur ADV7103 et le développement clinique FDA Advicenne Webconférence ATRd Sibnayal
BRIEF published on 09/19/2025 at 18:05, 1 year 1 month ago Advicenne: Half-year results in 2025 and outlook Financial Results Outlook Turnover United States Sibnayal®
BRIEF published on 09/19/2025 at 18:05, 1 year 1 month ago Advicenne : Résultats semestriels en 2025 et perspectives Chiffre D'affaires Résultats Financiers Perspectives États-Unis Sibnayal®
PRESS RELEASE published on 09/19/2025 at 18:00, 1 year 1 month ago Informations privilégiées / Communiqué sur comptes, résultats Advicenne présente ses résultats financiers semestriels au 30 juin 2025 et fait le point sur ses activités. Augmentation du chiffre d'affaires et perspectives favorables avec Sibnayal® Résultats Financiers Croissance Perspectives Advicenne Sibnayal®
BRIEF published on 07/28/2025 at 07:35, 1 year 3 months ago Advicenne Secures Marketing Authorization for Sibnayal® in Saudi Arabia Saudi Arabia Advicenne Reimbursement Sibnayal® DRTA
Published on 10/29/2026 at 08:00, 20 minutes ago Touchstone Exploration Provides an Operational Update
Published on 10/29/2026 at 07:30, 50 minutes ago Tocvan Pilot Mine Trench at Gran Pilar Averages 4.6 g/t Au With Samples Up to 24.4 g/t Au; New Zone 1.3 km East Returns Up to 234 g/t Ag
Published on 10/28/2026 at 22:35, 9 hours 45 minutes ago Route1 Announces Third Quarter and Year to Date 2026 Financial Results Notification
Published on 10/28/2026 at 12:30, 19 hours 50 minutes ago Digi Power X to Announce 2026 Q3 Financial Results and Provide Operations Update on November 13th
Published on 10/28/2026 at 12:30, 19 hours 50 minutes ago AI/ML Innovations Announces Advance Notice Provisions
Published on 10/29/2026 at 08:00, 20 minutes ago EQS-Adhoc: Henkel AG & Co. KGaA: Henkel achieves very strong organic sales growth in the third quarter and updates outlook for 2026
Published on 10/29/2026 at 08:00, 20 minutes ago Aquis Stock Exchange: Application for admission to trading
Published on 10/29/2026 at 07:20, 1 hour ago Q3 2026: Air Liquide accelerates, driven by sales growth and the launch of its strategic plan
Published on 10/29/2026 at 07:20, 1 hour ago T3 2026 : Air Liquide accélère, porté par des ventes en croissance et le lancement de son plan stratégique
